ORIC-944, a potential best-in-class PRC2 inhibitor, is being evaluated in combination with darolutamide and in combination with apalutamide in patients with mCRPC ORIC entered into clinical trial collaboration and supply agreements with Bayer and Johnson & Johnson SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc.

ORIC-944是一种潜在的同类最佳PRC2抑制剂，正在与达罗鲁胺联合使用，并与apalutamide联合使用，用于mCRPC ORIC患者，并于2024年7月16日与拜耳和强生南加州旧金山和加利福尼亚州圣地亚哥签订了临床试验合作和供应协议（Global NEWSWIRE）--ORIC Pharmaceuticals，Inc。

(Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced it initiated dosing of ORIC-944, a potent and selective allosteric inhibitor of PRC2, in combination with darolutamide as well as in combination with apalutamide, in the first half of 2024 as part of the ongoing Phase 1b trial in patients with metastatic prostate cancer.

（纳斯达克：ORIC）是一家专注于开发治疗耐药机制的临床阶段肿瘤公司，今天宣布，它在2024年上半年开始服用ORIC-944，这是一种有效且选择性的PRC2变构抑制剂，与达罗鲁胺以及阿帕鲁胺联合使用，作为正在进行的转移性前列腺癌患者1b期临床试验的一部分。

Each combination cohort includes a dose escalation and expansion portion, evaluating the combination of ORIC-944 and NUBEQA® (darolutamide) or ORIC-944 and ERLEADA® (apalutamide). The company also announced that it has entered into clinical trial collaboration and supply agreements with Bayer and Janssen Research & Development, LLC, a Johnson & Johnson company, to evaluate ORIC-944 in combination with NUBEQA®, Bayer’s androgen receptor (AR) inhibitor, and ERLEADA®, Johnson & Johnson’s AR inhibitor.

每个组合队列包括剂量递增和扩展部分，评估ORIC-944和NUBEQA®（达鲁酰胺）或ORIC-944和ERLEADA®（阿帕鲁酰胺）的组合。该公司还宣布，已与拜耳和强生公司Janssen Research＆Development，LLC签订临床试验合作和供应协议，以评估ORIC-944与拜耳雄激素受体（AR）抑制剂NUBEQA®和强生AR抑制剂ERLEADA®的组合。

Under the terms of the collaborations, ORIC® will continue to conduct and sponsor the ongoing Phase 1b trial, and Bayer and Johnson & Johnson will provide darolutamide and apalutamide, respectively, for the study. ORIC maintains full global development and commercial rights to ORIC-944. “We are pleased to enter into these clinical collaborations to investigate the broader potential of ORIC-944 in combination with AR inhibitors, a combination approach that we believe is particularly promisin.

根据合作条款，ORIC®将继续进行并赞助正在进行的1b期试验，拜耳和强生将分别为该研究提供达罗鲁胺和阿帕鲁胺。ORIC拥有ORIC-944的全部全球开发和商业权利。“我们很高兴参与这些临床合作，以研究ORIC-944与AR抑制剂联合使用的更广泛潜力，我们认为这种联合方法特别有前景。